Xenetic Biosciences, Inc.
XBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $2 | $1 |
| % Growth | -1.6% | 48.8% | 47.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $3 | $2 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $3 | $3 | $5 | $3 |
| G&A Expenses | $3 | $4 | $4 | $4 |
| SG&A Expenses | $3 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $7 | $8 | $7 |
| Operating Income | -$4 | -$5 | -$7 | -$6 |
| % Margin | -168.2% | -177.8% | -393.6% | -495.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$4 | -$7 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$4 | -$7 | -$6 |
| % Margin | -158.4% | -162.8% | -383.9% | -486.4% |
| EPS | -2.57 | -2.71 | -4.49 | -5.39 |
| % Growth | 5.2% | 39.6% | 16.7% | – |
| EPS Diluted | -2.57 | -2.71 | -4.49 | -5.39 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$7 | -$6 |
| % Margin | -162% | -177.8% | -392% | -492.1% |